KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Debt to Equity (2019 - 2025)

Vir Biotechnology's Debt to Equity history spans 5 years, with the latest figure at $0.02 for Q1 2025.

  • For Q1 2025, Debt to Equity changed N/A year-over-year to $0.02; the TTM value through Mar 2025 reached $0.02, changed N/A, while the annual FY2024 figure was $0.01, N/A changed from the prior year.
  • Debt to Equity for Q1 2025 was $0.02 at Vir Biotechnology, up from $0.01 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.08 in Q3 2021 and bottomed at $0.01 in Q4 2024.
  • The 3-year median for Debt to Equity is $0.04 (2021), against an average of $0.04.
  • The largest YoY upside for Debt to Equity was 326.24% in 2021 against a maximum downside of 33.24% in 2021.
  • A 3-year view of Debt to Equity shows it stood at $0.08 in 2021, then crashed by 82.14% to $0.01 in 2024, then rose by 20.09% to $0.02 in 2025.
  • Per Business Quant, the three most recent readings for VIR's Debt to Equity are $0.02 (Q1 2025), $0.01 (Q4 2024), and $0.08 (Q3 2021).